Registered South Africa · SAHPRA

ANXILO

ETIFOXINE HYDROCHLORIDE

59/2.6/0225.224 nervous system INN generic

What it does

Etifoxine is a medication that helps reduce anxiety and improve mood.

Commonly used for: anxiety disorders, stress-related conditions

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
59/2.6/0225.224
Registration date
2026/03/24
Expiry date
-
Status
Registered
Active ingredient
ETIFOXINE HYDROCHLORIDE
Dosage form
-
Strength
-
Pack size
-
Therapeutic class
-
ATC class (WHO)
N05BX - Other anxiolytics
Drug group
NERVOUS SYSTEM
RxNorm RxCUI
24441
Manufacturer / MAH
-
Country of origin
-

Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:30:28 · updated 2026-09-16 04:01:14

Disclaimer: This information is sourced from South African Health Products Regulatory Authority (South Africa). Always consult a qualified healthcare professional before using any medication.

About this medicine

Etifoxine is a medication that helps reduce anxiety and improve mood.

What it treats

  • anxiety disorders
  • stress-related conditions

How it works

Etifoxine works by calming the brain and helping to improve feelings of anxiety.

Who it's for

It is for adults experiencing anxiety or stress.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: etifoxine

BNF-referenced

Etifoxine is an anxiolytic agent primarily used for the treatment of anxiety disorders. It is known for its neuroprotective properties and is considered to enhance the action of GABA, which is a major inhibitory neurotransmitter in the central nervous system. This drug may be utilized in various clinical settings to manage anxiety-related symptoms and improve patient well-being.

Indications

  • Anxiety disorders
  • Generalized anxiety disorder
  • Panic disorder
  • Acute stress reactions

Dosage

Children: Refer to the BNF for Children for paediatric dosing recommendations as they are not specified here.

Adults: The usual adult dosage is 100 mg to 200 mg taken orally, divided into two or three doses per day.

Mechanism of action

Etifoxine acts by enhancing the action of GABA at the GABA-A receptor, leading to increased chloride ion influx and hyperpolarization of neuronal membranes. It is also thought to modulate neurosteroid levels, which contribute to its anxiolytic effects, promoting a calming effect without the sedative properties typically associated with benzodiazepines.

Pharmacodynamics

Etifoxine exhibits anxiolytic effects through its action on GABA receptors, leading to reduced neuronal excitability. Its neuroprotective properties may result from its ability to modulate neurosteroid levels and influence brain-derived neurotrophic factor (BDNF), which is important for neuronal survival and plasticity.

Pharmacokinetics

Etifoxine is well-absorbed following oral administration, with peak plasma concentrations typically reached within a few hours. It is metabolized in the liver, with various pathways leading to the formation of active metabolites. The drug has a moderate half-life, allowing for once or twice daily dosing. Elimination is primarily via the kidneys.

Contra-indications

  • Hypersensitivity to etifoxine or any of its components
  • Severe hepatic impairment

Adverse effects

  • Drowsiness
  • Fatigue
  • Dizziness
  • Nausea
  • Skin rash
  • Gastrointestinal disturbances

Interactions

  • Caution is advised when used with central nervous system depressants
  • May enhance the effects of alcohol

Precautions

  • Use with caution in patients with a history of liver disease
  • Monitor for signs of sedation or excessive drowsiness

Pregnancy

There is limited data on the use of etifoxine in pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether etifoxine is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Formulations

  • Tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: etifoxine

PubChem CID 135413553

Molecular formula: C17H17ClN2O

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.